Literature DB >> 9590220

Expression of bright at two distinct stages of B lymphocyte development.

C F Webb1, E A Smith, K L Medina, K L Buchanan, G Smithson, S Dou.   

Abstract

The B cell regulator of Ig heavy chain transcription (Bright) is a DNA-binding protein that was originally discovered in a mature Ag-specific B cell line after stimulation with IL-5 and Ag. It binds to the intronic heavy chain enhancer and 5' of the V1 S107 family V(H) promoter. Several studies suggested that Bright may increase transcription of the heavy chain locus, and expression in cell lines was limited to those representing mature B cells. We have now analyzed normal hemopoietic tissues for the expression of Bright during B lymphocyte differentiation. We expected to find Bright expression in a subset of mature spleen cells, but also observed Bright in a subset of normal B lymphocytic progenitors in both adult bone marrow (BM) and in fetal liver as early as day 12 of gestation. Bright was also expressed in the small percentage of CD4(low) cells in the thymus that are newly arrived from the BM and are not yet committed to the T lymphocyte lineage, but was not observed at later stages of T cell differentiation in either the spleen or thymus. Bright mRNA was not detected in the immature B lymphocytes that initially populate the spleen after migration from the BM. In addition, new splice variants of Bright were observed in fetal tissues. Thus, Bright expression is highly regulated in normal murine lymphocytes and occurs both early and late during B cell differentiation. These findings may have important implications for the function of Bright in regulating Ig transcription.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9590220

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  27 in total

1.  The transcription factor Bright plays a role in marginal zone B lymphocyte development and autoantibody production.

Authors:  Athenia L Oldham; Cathrine A Miner; Hong-Cheng Wang; Carol F Webb
Journal:  Mol Immunol       Date:  2011-10-02       Impact factor: 4.407

2.  The ARID family transcription factor bright is required for both hematopoietic stem cell and B lineage development.

Authors:  Carol F Webb; James Bryant; Melissa Popowski; Laura Allred; Dongkoon Kim; June Harriss; Christian Schmidt; Cathrine A Miner; Kira Rose; Hwei-Ling Cheng; Courtney Griffin; Philip W Tucker
Journal:  Mol Cell Biol       Date:  2011-01-03       Impact factor: 4.272

3.  Characterization of a new ARID family transcription factor (Brightlike/ARID3C) that co-activates Bright/ARID3A-mediated immunoglobulin gene transcription.

Authors:  Josephine A Tidwell; Christian Schmidt; Phillip Heaton; Van Wilson; Philip W Tucker
Journal:  Mol Immunol       Date:  2011-09-28       Impact factor: 4.407

4.  Signalling of the BCR is regulated by a lipid rafts-localised transcription factor, Bright.

Authors:  Christian Schmidt; Dongkyoon Kim; Gregory C Ippolito; Hassan R Naqvi; Loren Probst; Shawn Mathur; German Rosas-Acosta; Van G Wilson; Athenia L Oldham; Martin Poenie; Carol F Webb; Philip W Tucker
Journal:  EMBO J       Date:  2009-02-12       Impact factor: 11.598

Review 5.  Complementary regulation of early B-lymphoid differentiation by genetic and epigenetic mechanisms.

Authors:  Takafumi Yokota; Takao Sudo; Tomohiko Ishibashi; Yukiko Doi; Michiko Ichii; Kenji Orirani; Yuzuru Kanakura
Journal:  Int J Hematol       Date:  2013-09-03       Impact factor: 2.490

6.  Loss of Bright/ARID3a function promotes developmental plasticity.

Authors:  Guangyu An; Cathrine A Miner; Jamee C Nixon; Paul W Kincade; James Bryant; Philip W Tucker; Carol F Webb
Journal:  Stem Cells       Date:  2010-09       Impact factor: 6.277

7.  Bruton's tyrosine kinase regulates immunoglobulin promoter activation in association with the transcription factor Bright.

Authors:  Jaya Rajaiya; Melissa Hatfield; Jamee C Nixon; David J Rawlings; Carol F Webb
Journal:  Mol Cell Biol       Date:  2005-03       Impact factor: 4.272

8.  Transgenic mice expressing dominant-negative bright exhibit defects in B1 B cells.

Authors:  Jamee C Nixon; Scott Ferrell; Cathrine Miner; Athenia L Oldham; Ute Hochgeschwender; Carol F Webb
Journal:  J Immunol       Date:  2008-11-15       Impact factor: 5.422

Review 9.  Perspectives on fetal derived CD5+ B1 B cells.

Authors:  Richard R Hardy; Kyoko Hayakawa
Journal:  Eur J Immunol       Date:  2015-09-23       Impact factor: 5.532

10.  Differential expression of the transcription factor ARID3a in lupus patient hematopoietic progenitor cells.

Authors:  Michelle L Ratliff; Julie M Ward; Joan T Merrill; Judith A James; Carol F Webb
Journal:  J Immunol       Date:  2014-12-22       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.